YU25295A - Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima - Google Patents

Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima

Info

Publication number
YU25295A
YU25295A YU25295A YU25295A YU25295A YU 25295 A YU25295 A YU 25295A YU 25295 A YU25295 A YU 25295A YU 25295 A YU25295 A YU 25295A YU 25295 A YU25295 A YU 25295A
Authority
YU
Yugoslavia
Prior art keywords
alendronate
patients
implant device
medicament
prevention
Prior art date
Application number
YU25295A
Other languages
English (en)
Inventor
Alej J. Yates
Original Assignee
Merck And Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck And Co.Inc. filed Critical Merck And Co.Inc.
Publication of YU25295A publication Critical patent/YU25295A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Opisana je upotreba bisfosfonatnog inhibitora resorpcije kosti, na pr., alendronata u proizvodnji leka za tretiranje i sprečavanje periproteznog gubitka kosti, kod pacijenata koji imaju ortopedsko implanirano sredstvo.
YU25295A 1994-04-21 1995-04-19 Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima YU25295A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/230,670 US5646134A (en) 1994-04-21 1994-04-21 Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Publications (1)

Publication Number Publication Date
YU25295A true YU25295A (sh) 1999-09-27

Family

ID=22866129

Family Applications (1)

Application Number Title Priority Date Filing Date
YU25295A YU25295A (sh) 1994-04-21 1995-04-19 Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima

Country Status (29)

Country Link
US (3) US5646134A (sh)
EP (2) EP0756483B1 (sh)
JP (1) JPH09512268A (sh)
CN (1) CN1078073C (sh)
AT (1) ATE236641T1 (sh)
AU (1) AU2374895A (sh)
BG (1) BG63102B1 (sh)
CA (1) CA2188030C (sh)
CO (1) CO4370025A1 (sh)
CZ (1) CZ305596A3 (sh)
DE (1) DE69530293T2 (sh)
DK (1) DK0756483T3 (sh)
DZ (1) DZ1873A1 (sh)
ES (1) ES2194050T3 (sh)
FI (1) FI964213A (sh)
HR (1) HRP950239A2 (sh)
HU (1) HUT74911A (sh)
IL (1) IL113361A (sh)
MY (1) MY114265A (sh)
NO (1) NO312124B1 (sh)
NZ (1) NZ284295A (sh)
PL (1) PL318552A1 (sh)
PT (1) PT756483E (sh)
RU (1) RU2161032C2 (sh)
SK (1) SK133396A3 (sh)
TW (1) TW406021B (sh)
WO (1) WO1995028936A1 (sh)
YU (1) YU25295A (sh)
ZA (1) ZA953185B (sh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
JP2000504718A (ja) * 1996-02-14 2000-04-18 バインダーマン，イザク 骨吸収を予防するための局所用ビスホスホネート
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
EE05603B1 (et) * 1997-07-22 2012-12-17 Merck & Co., Inc. Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
DE69927048T2 (de) 1998-12-04 2006-06-08 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
US6727233B1 (en) * 1998-12-25 2004-04-27 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
CA2370769A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
AU2001287260A1 (en) * 2000-07-12 2002-01-21 Ecole Polytechnique Federale De Lausanne (Epfl) Active biocoating for bone implant
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
WO2002040073A1 (en) * 2000-11-20 2002-05-23 Université De Genève Endosseous implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CN1233325C (zh) * 2001-02-06 2005-12-28 罗亚尔·亚历山德拉儿童医院 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
US20040157798A1 (en) * 2001-04-03 2004-08-12 Little David Graham Drug for use in bone grafting
KR20020080018A (ko) * 2001-04-10 2002-10-23 한국화학연구원 비스포스포네이트 골 흡수억제제의 이식형 서방성제제
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1504033A2 (en) * 2002-05-03 2005-02-09 Millenium Biologix Inc. Connective tissue stimulating peptides
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US7674454B2 (en) * 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
EP2473172B1 (en) 2009-09-01 2015-04-08 Duke University Bisphosphonate compositions and methods for treating heart failure
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
BR112013010476B1 (pt) * 2010-12-06 2021-07-06 Effrx Pharmaceuticals Sa formulações efervescentes estáveis de bisfosfonato com características de solubilização rápida
US8858979B1 (en) 2011-01-28 2014-10-14 Clemson University Service induced byproducts for localized drug delivery in orthopaedic implants
KR102072250B1 (ko) * 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
RU2653627C1 (ru) * 2016-11-09 2018-05-11 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Способ моделирования асептического аминобисфосфонатного остеонекроза нижней челюсти у лабораторных белых крыс
US12029640B2 (en) 2017-12-07 2024-07-09 Paul V. Fenton, Jr. Method and injection system for bone tissue implant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
CN1046853C (zh) * 1988-01-20 1999-12-01 山之内制药株式会社 制备药用组合物的方法
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
JPH07507315A (ja) * 1992-05-29 1995-08-10 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド カルシウムおよびホスフェート代謝異常治療用含硫ホスホネート化合物
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (fi) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Also Published As

Publication number Publication date
NZ284295A (en) 2000-06-23
HUT74911A (en) 1997-03-28
US5891863A (en) 1999-04-06
HRP950239A2 (en) 1997-04-30
TW406021B (en) 2000-09-21
DE69530293D1 (de) 2003-05-15
NO964441D0 (no) 1996-10-18
PL318552A1 (en) 1997-06-23
NO312124B1 (no) 2002-03-25
CA2188030C (en) 2003-07-29
HU9602888D0 (en) 1996-12-30
DE69530293T2 (de) 2004-02-05
WO1995028936A1 (en) 1995-11-02
MY114265A (en) 2002-09-30
ZA953185B (en) 1995-12-27
CZ305596A3 (en) 1997-06-11
JPH09512268A (ja) 1997-12-09
FI964213A0 (fi) 1996-10-18
EP0756483A1 (en) 1997-02-05
ATE236641T1 (de) 2003-04-15
RU2161032C2 (ru) 2000-12-27
NO964441L (no) 1996-10-18
SK133396A3 (en) 1997-05-07
US5972913A (en) 1999-10-26
CA2188030A1 (en) 1995-11-02
DZ1873A1 (fr) 2002-02-17
AU2374895A (en) 1995-11-16
CN1078073C (zh) 2002-01-23
EP1197213A2 (en) 2002-04-17
DK0756483T3 (da) 2003-04-28
FI964213A (fi) 1996-10-18
CO4370025A1 (es) 1996-10-07
IL113361A0 (en) 1995-07-31
CN1146152A (zh) 1997-03-26
EP1197213A3 (en) 2002-09-25
EP0756483B1 (en) 2003-04-09
BG63102B1 (bg) 2001-04-30
IL113361A (en) 1999-11-30
BG100910A (en) 1998-03-31
PT756483E (pt) 2003-07-31
ES2194050T3 (es) 2003-11-16
US5646134A (en) 1997-07-08

Similar Documents

Publication Publication Date Title
YU25295A (sh) Primena alendronata u proizvodnji leka za sprečavanja periproteznog gubitka kosti kod pacijenata sa ortopedskim implantiranim sredstvima
McCarthy The role of distraction osteogenesis in the reconstruction of the mandible in unilateral craniofacial microsomia
EP0777484A4 (en) INTRAVENOUS ALENDRONATE FORMULATIONS
RU96121563A (ru) Использование бисфосфонатов для ингибирования резорбции кости, возникающей вследствие имплантации ортопедических протезов
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
SE9102778D0 (sv) Implanterbar medicinsk anordning
NO924697D0 (no) Kirurgisk implantat og en fremgangsmaate for behandling avkirurgisk implantat
DE60308256D1 (de) Beschichtetes medizinsches Implantat zur Behandlung von Gefässerkrankungen
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
HK1061797A1 (en) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
Figueroa et al. Intraoral-appliance modification to retract the premaxilla in patients with bilateral cleft lip
Cundy et al. A ten-year review of treatment of delayed union and nonunion with an implanted bone growth stimulator
MX9604968A (es) Uso de bisfosfonatos para inhibir la reabsorcion de hueso despues de la implantacion de protesis ortopedicas.
FI953514A0 (fi) Uusi osteoblastien proliferaatiotekijä
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
UA43800A (uk) Спосіб лікування перфоративної виразки дванадцятипалої кишки
AUPM497994A0 (en) Improved orthotic device for the treatment and rehabilitation of fractures of the tibia incorporating therapeutic pulsed electromagnetic field therapy
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
GEU2003994Y (en) Protobe (HA-protobe)-Hydroxyapatite
AUPM497694A0 (en) Improved orthotic device for the treatment of soft tissue injuries of the groin incorporating therapeutic pulsed electromagnetic field therapy
UA5498A1 (uk) Пристрій для корекції вальгусного відхилення першого пальця стопи
AUPM497594A0 (en) Improved orthotic device for the treatment of knee joint disorders incorporating therapeutic pulsed electromagnetic field therapy